ClinicalTrials.gg
RecruitingNCT061612073D-4K-ICGUpdated Jun 24, 2024

3D-4K-ICG Laparoscopic Gastrectomy for Gastric Cancer

A Phase 3 interventional study of Indocyanine Green Tracer Using in 3D plus Ultra High Resolution Laparoscopic Gastrectomy with Lymph Node Dissection in Gastric Cancer and Surgery, sponsored by Fujian Medical University. Recruiting at 1 site in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2024-06-24.

Sponsored by Fujian Medical University · Phase 3, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Jan 2026, 10 months ago, but the record still lists the study as recruiting.
  • Registered 10 months after the study started (first participant enrolled Jan 2023, registered Nov 2023).
  • Started Jan 2023; still recruiting 3 years 10 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
702
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 56 studies in Stomach Neoplasms by Fujian Medical University — 16 open to participants now, 20 under way, 6 of them phase 3. Stomach Neoplasms · Fujian Medical University.

Planned enrollment
2nd of 32
702 · median 192
Started
2023
with 6 others
Phase 3
7 of 56
5 open now
Primary completion
2026-01
later than 14 of 19 live
Registered
41st of 56
by date

Among the 56 studies in Stomach Neoplasms by Fujian Medical University, this one is the 2nd largest by planned enrollment of the 32 interventional ones that give a count, is one of 7 that started in 2023, is one of 7 in phase 3, reaches primary completion later than 14 of the 19 other live ones, and was the 41st registered.

Stomach Neoplasms

3,407 studies on the registry are indexed under Stomach Neoplasms; 994 are open to participants now.

Browse Stomach Neoplasms studies →

Open to participants now

16 of the 56 studies in Stomach Neoplasms by Fujian Medical University are open now, in 1 country. Recruiting first, the newest first:

10 more — sign in →

By country, each count listing its studies:

All 16 open studies →

Where they have run

Who these studies take

Of the 704 Stomach Neoplasms studies recruiting now, 375 (53%) set no upper age limit and 194 (28%) stop at 75 or younger; 27 take children under 18; 70 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 56 studies in Stomach Neoplasms by Fujian Medical University, or all of them as a file.
02

Study summary

Patients with locally advanced gastric adenocarcinoma (CT2-4a N-/+ M0) were selected as study subjects to investigate the safety, efficacy, and feasibility of ICG near-infrared imaging tracing in 3D plus ultra high resolution laparoscopic gastrectomy with lymph node dissection for gastric cancer.

Read the detailed description
  1. Research purpose: Patients with locally advanced gastric adenocarcinoma (CT2-4a N-/+ M0) were selected as study subjects to investigate the safety, efficacy, and feasibility of ICG near-infrared imaging tracing in 3D plus ultra high resolution laparoscopic gastrectomy with lymph node dissection for gastric cancer.
  2. Research design: Prospective, single-center, randomized controlled, open-control, parallel assignment, superiority test.

2.1 Case group Group A (Study Group 1, 234 cases): ICG near-infrared imaging tracing in 3D plus ultra high resolution laparoscopic gastrectomy with lymph node dissection; Group B (Study Group 2, 234 cases): ICG near-infrared imaging tracing in ultra high resolution laparoscopic gastrectomy with lymph node dissection; Group C (Control Group 2, 234 cases) 3D laparoscopic gastrectomy with lymph node dissection

2.2 Estimate Sample Size The three-year disease-free survival (DFS) was the main effectiveness evaluation index in this study. The study implemented a superiority test (unilateral), assuming that both the study group's three-year DFS would be better than that of control group, according to previous research results of laparoscopic surgery for locally advanced GC in which the three-year DFS was 65.2%; therefore, the 3-year DFS of the control group would be 65.2%, assuming that the 3-year DFS of the experimental group could be increased by 12% to 77.2%. With an inspection level 0.0125 (unilateral) and an inspection efficiency of 0.8 and using PASS 11 log-rank tests (Lakatos) [Proportion surviving] the calculated sample size was N=211; namely, each group needed 211 people, considering cases of possible exclusion and loss to follow-up (10% drop out rate). The final sample size for each group was 234 cases, for a total of 702 cases.

2.3 randomization After laparoscopic exploration and confirmation that the cases complied with the standards, they were included in the randomized groups in this study. SAS 9.2 was used to produce a serial number ranging from 0001 - 702 corresponding to the treatment allocation, which was reserved in the data center and research center.

2.4 Blinding Method: This research adopts an open design.

2.5 Research cycle: Estimated enrollment cycle: complete enrollment within 2 years. Follow-up period: the enrollment of the first case was the starting point for follow-up. And the enrollment of last case to the postoperative pathology report (generally 2 weeks after surgery) was the endpoint of follow-up for secondary outcomes. Three years after the last case was enrolled was the follow-up endpoint for the main outcomes.

Estimated time: 2023.12-2025.12 (complete enrollment) to 2028.12 (complete follow-up)

Study Objects All patients who meet the inclusion criteria and do not conform to the exclusion criteria are qualified for this study.

03

Conditions studied

  • Gastric Cancer
  • Surgery

Browse trials for

Keywords

  • Indocyanine Green Tracer
  • Laparoscopic Gastrectomy
  • Gastric Cancer
  • Ultra High Resolution
  • 3D
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age from 18 to 75 years
  2. Primary gastric adenocarcinoma (papillary, tubular, mucinous, signet ring cell, or poorly differentiated) confirmed pathologically by endoscopic
  3. cT2-4a, N-/+, M0 at preoperative evaluation according to the AJCC Cancer Staging Manual, 8th Edition
  4. No distant , no direct invasion of pancreas, spleen or other adjacent organs in the preoperative examinations
  5. Performance status of 0 or 1 on the (Eastern Cooperative Oncology Group) scale
  6. ASA (American Society of Anesthesiology) class I to III
  7. Written

Exclusion criteria

Exclusion Criteria:

  1. Women during pregnancy or breast-feeding
  2. Severe mental disorder
  3. History of previous upper abdominal surgery (except for laparoscopic cholecystectomy)
  4. History of previous gastric surgery (including ESD/EMR for gastric cancer)
  5. Enlarged or bulky regional lymph node (diameter over 3cm) supported by preoperative imaging
  6. Other malignant disease within the past 5 years
  7. History of previous chemotherapy or radiotherapy
  8. History of unstable angina or myocardial infarction within past six months
  9. History of cerebrovascular accident within past six months
  10. History of continuous systematic administration of within one month
  11. Requirement for simultaneous surgery for other disease
  12. Emergency surgery due to complication (bleeding, obstruction or perforation) caused by gastric cancer
  13. (forced expiratory volume in one second)\<50% of predicted values
  14. Diffuse invasive gastric cancer
  15. History of an iodine allergy
  16. Patients who declined laparoscopic surgery
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
702 participants (estimated)

Study arms

  • Experimental
    3D-4K-ICG

    Indocyanine Green Tracer Using in 3D plus Ultra High Resolution Laparoscopic Gastrectomy with Lymph Node Dissection

    Procedure: Indocyanine Green Tracer Using in 3D plus Ultra High Resolution Laparoscopic Gastrectomy with Lymph Node Dissection

  • Experimental
    4K-ICG

    Indocyanine Green Tracer Using in Ultra High Resolution Laparoscopic Gastrectomy with Lymph Node Dissection

    Procedure: Indocyanine Green Tracer Using in 3D plus Ultra High Resolution Laparoscopic Gastrectomy with Lymph Node Dissection

  • Placebo comparator
    3D

    3D Laparoscopic Gastrectomy with Lymph Node Dissection

    Procedure: Indocyanine Green Tracer Using in 3D plus Ultra High Resolution Laparoscopic Gastrectomy with Lymph Node Dissection

Interventions

  • ProcedureIndocyanine Green Tracer Using in 3D plus Ultra High Resolution Laparoscopic Gastrectomy with Lymph Node Dissection

    Indocyanine green tracer is used with 3D plus ultra high resolution laparoscopic gastrectomy with lymph node Dissection for gastric cancer

06

What researchers measure

Primary outcomes

  1. 3-year disease free survival rate

    Disease-free survival is calculated from the day of surgery to the day of recurrence or death

    Time frame: 3 years

Secondary outcomes

  1. Operation time

    Operation time

    Time frame: 1 day

  2. Total number of retrieved lymph nodes

    Total number of retrieved lymph nodes

    Time frame: 1 day

  3. Noncompliance rate of lymph node dissection

    Noncompliance rate of lymph node dissection

    Time frame: 1 day

  4. Relationship between fluorescent lymph nodes in group A and total number of lymph nodes in group A

    Relationship between fluorescent lymph nodes in group A and total number of lymph nodes in group A

    Time frame: 1 day

  5. Relationship between fluorescent lymph nodes in Group A and positive lymph nodes in Group A (positive rate)

    Relationship between fluorescent lymph nodes in Group A and positive lymph nodes in Group A (positive rate)

    Time frame: 1 day

  6. Relationship between fluorescent lymph nodes in Group A and negative lymph nodes in Group A (false positive rate)

    Relationship between fluorescent lymph nodes in Group A and negative lymph nodes in Group A (false positive rate)

    Time frame: 1 day

  7. Relationship between non-fluorescent lymph nodes in Group A and negative lymph nodes in group A (negative rate)

    Relationship between non-fluorescent lymph nodes in Group A and negative lymph nodes in group A (negative rate)

    Time frame: 1 day

  8. Relationship between nonfluorescent lymph nodes in Group A and positive lymph nodes in Group A (false negative rate)

    Relationship between nonfluorescent lymph nodes in Group A and positive lymph nodes in Group A (false negative rate)

    Time frame: 1 day

  9. Relationship between fluorescent lymph nodes in group B and total number of lymph nodes in group B

    Relationship between fluorescent lymph nodes in group B and total number of lymph nodes in group B

    Time frame: 1 day

  10. Relationship between fluorescent lymph nodes in Group B and positive lymph nodes in Group B (positive rate)

    Relationship between fluorescent lymph nodes in Group B and positive lymph nodes in Group B (positive rate)

    Time frame: 1 day

  11. Relationship between fluorescent lymph nodes in Group B and negative lymph nodes in Group B (false positive rate)

    Relationship between fluorescent lymph nodes in Group A and negative lymph nodes in Group A (false positive rate)

    Time frame: 1 day

  12. Relationship between non-fluorescent lymph nodes in Group B and negative lymph nodes in group B (negative rate)

    Relationship between non-fluorescent lymph nodes in Group B and negative lymph nodes in group B (negative rate)

    Time frame: 1 day

  13. Relationship between nonfluorescent lymph nodes in Group B and positive lymph nodes in Group B (false negative rate)

    Relationship between nonfluorescent lymph nodes in Group B and positive lymph nodes in Group B (false negative rate)

    Time frame: 1 day

  14. Number of metastatic lymph nodes

    Number of metastatic lymph nodes

    Time frame: 1 day

  15. Metastasis rate of lymph nodes

    Metastasis rate of lymph nodes

    Time frame: 1 day

  16. Morbidity and mortality rates

    Morbidity and mortality rates

    Time frame: 30 day

  17. 3-year overall survival rate

    3-year overall survival rate

    Time frame: 3 years

  18. 3-year recurrence pattern

    3-year recurrence pattern

    Time frame: 3 years

  19. Postoperative recovery course

    Postoperative recovery course

    Time frame: 30 days

  20. Intraoperative situation

    Intraoperative situation

    Time frame: 30 days

  21. Postoperative nutritional status

    Postoperative nutritional status

    Time frame: 3 years

  22. Inflammatory and immune response

    Inflammatory and immune response

    Time frame: 30 days

  23. Postoperative quality of life (measured by EQ-5D)

    Postoperative quality of life (measured by EQ-5D)

    Time frame: preoperative, postoperative 1 month and postoperative 1 year

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jan 2023 (actual). Primary completion is estimated for Jan 2026, 35 months after the start.

Of 73 non-industry phase 3 interventional studies under Stomach Neoplasms, half reached primary completion within 79 months of starting (the median), counting those still running; a quarter within 46 and three quarters within 144. This study's planned 35 months is below that.

Counting every sponsor, half of 118 studies reached it within 52 months; a quarter within 39 and three quarters within 96.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 30, 2023
First posted
Dec 7, 2023
StartActual
Jan 3, 2023
Primary completionEst.
Jan 1, 2026
CompletionEst.
Jan 1, 2029
Last update
Jun 24, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 24, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06161207
Responsible party
Chang-Ming Huang, Prof. (Professor, Fujian Medical University Union Hospital) — Principal investigator
First posted
Dec 7, 2023
Start date
Jan 3, 2023
Primary completion
Jan 1, 2026 (estimated)
Completion
Jan 1, 2029 (estimated)
Last update
Jun 24, 2024

Study contacts

Mi Lin
Contact
silihuala@qq.com
13459152658
Hua-Long Zheng
Contact
291167038@qq.com
18359190587
Chang-ming Huang
principal investigator · Fujian Medical University Union Hospital

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion